B. Metzler Seel. Sohn & Co. Ag Alnylam Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 3,279 shares of ALNY stock, worth $889,625. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,279
Previous 4,017
18.37%
Holding current value
$889,625
Previous $976,000
7.68%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ALNY
# of Institutions
650Shares Held
109MCall Options Held
1.28MPut Options Held
1.23M-
Capital World Investors Los Angeles, CA16.5MShares$4.48 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.43 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.59 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.42 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.34 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.4B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...